Compare PubMatic Inc (PUBM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs Twist Bioscience Corp — how do they compare? PubMatic Inc trades at $18.82 (market cap $850.88M), while Twist Bioscience Corp trades at $167.1 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 11.8× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold PubMatic Inc for 40 Days and Twist Bioscience Corp for 27 Days on average.
| PUBM | TWST | |
|---|---|---|
Market Cap | $850.88M | $10.08B |
Volume | 997,698 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $19.18 | $205.00 |
52-Week Low | $6.28 | $25.45 |
Typical Hold Time | 40 Days | 27 Days |
Enterprise Value | $754.01M | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PubMatic (PUBM) trades at $19.02, up 2.42% with a bullish technical signal and strong analyst consensus. The company shows mixed fundamentals with negative net income margins but positive cash flow and recent earnings beats. Recent Q2 2026 results exceeded expectations with 11% revenue growth, driven by mobile app and CTV segments. Technical indicators show bullish moving averages with neutral oscillators, while support sits at $18 and resistance at $19.
The outlook remains cautiously optimistic with 64.7% analyst buy ratings and a $19.89 price target. Key opportunities include AI-driven ad growth and market share gains, while risks involve persistent profitability challenges and competitive pressures in digital advertising. The CFO's planned retirement adds transitional uncertainty.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
